Recently stock market analysts have updated their consensus ratings on shares of Bio-Rad Laboratories, Inc. (NYSE:BIO). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

08/07/2015 – Bio-Rad Laboratories, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 200 price target on the stock.

05/08/2015 – Bio-Rad Laboratories, Inc. was upgraded to “strong-buy” by analysts at Zacks. They now have a USD 167 price target on the stock.

05/07/2015 – Bio-Rad Laboratories, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 140 price target on the stock.

09/19/2014 – Bio-Rad Laboratories, Inc. was downgraded to “hold” by analysts at TheStreet.

05/26/2014 – Bio-Rad Laboratories, Inc. was downgraded to “hold” by analysts at ING.

Bio-Rad Laboratories, Inc. has a 50 day moving average of 138.87 and a 200 day moving average of 135.77. The stock’s market capitalization is 4.15B, it has a 52-week low of 122.03 and a 52-week high of 152.38.

The share price of the company (NYSE:BIO) was down -1.23% during the last trading session, with a high of 143.70 and the volume of Bio-Rad Laboratories, Inc. shares traded was 321367.

View other investors thoughts on Bio-Rad Laboratories, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.